Over 160 people. 
One shared standard  of execution.

Meri is a former life sciences and healthtech venture capital investor, with an MSc in Biology from the University of Oxford. Serving on the boards of health and biotech companies, he saw CROs repeatedly fail to deliver clinical trials on time and on budget. After participating in a COVID-19 vaccine trial, he saw how fragmented integrated technology, poor patient experience and operational problems at sites cascaded up to the cost and timeline overruns he experienced as an investor. He founded Lindus to fix these problems and provide a more accountable, predictable model for research.

Michael was previously a Special Adviser to the UK Prime Minister, where he advised on a range of issues including life sciences. Before serving in government, he worked at McKinsey & Company and L.E.K. Consulting, predominantly on commercialization and strategy in the healthcare space. His time in government during the pandemic showed him how much trial delivery depended on fragmented, outdated infrastructure, and convinced him the industry needed a fundamentally different operating model; without this none of the groundbreaking advances in understanding human biology will ever benefit patients. He founded Lindus to fix these bottlenecks.

Gemma leads R&D of CitrusTM, Lindus’ AI-native operating system. She is a technology executive who has spent her career building and scaling engineering teams. Before Lindus she spent three years as a Principal Software Engineering Manager at Microsoft, leading teams of up to 30 engineers on Telecoms products in Azure. Prior to that she spent 23 years at Metaswitch Networks, advancing from Software Engineer to Senior Software Engineering Manager. She holds a BA in Mathematics and a Diploma in Computer Science from the University of Cambridge, and is an active advocate for women in technology.

Heather has over 30 years of experience in clinical operations, spanning clinical site, biotech, and CRO environments. She co-founded Highline Sciences, an oncology-focused CRO, and served as its COO, scaling the company from seven employees to over 100 before its acquisition by Tempus AI. She remained as COO of Tempus Compass, integrating technology with clinical operations and supporting the company through its IPO. Her earlier career includes senior roles at Precision For Medicine, SynteractHCR, and Novella Clinical (now IQVIA), across oncology, immunology, and neurology.

Luke is a physician with nearly three decades of clinical and leadership experience. He was Lindus employee number three. He previously served as CEO of Omnes Healthcare, delivering dermatology, ENT, diagnostic, and general practice services to the NHS, and directed clinical governance at UnitedHealth Group (Optum). He continues to practise as a GP alongside his role at Lindus, bringing frontline clinical perspective to the medical oversight of every trial. He trained at the Universities of Oxford and Cambridge, and holds an MBA from Durham University.

Rich is a clinical research executive with over two decades in oncology trial management. He built his foundation during an 11-year tenure at PPD, progressing from Research Associate to Project Manager across global oncology programmes. He went on to lead immuno-oncology project management at IQVIA Biotech, then held senior roles at Novella Clinical (now IQVIA), KCR, Vial, and ICON Biotech. His career spans Phase I through Phase IV oncology studies, with particular depth in immuno-oncology clinical strategy and global trial oversight.

Veronica is a clinical data management leader with over a decade of experience in designing and delivering clinical trials. At Lindus, she built and scaled the global Deployment team - leading the design, configuration, and UAT of new clinical trials on CitrusTM, Lindus’ AI-native operating system. Previously, she led data and delivery teams at Verily Life Sciences, where she was the data management lead for their first decentralized drug trial, and at Faro Health, where she shaped the data management strategy within the Product organization.